Search

Displaying results 1041 - 1050 of 1786 in total
  1. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    [A239249] Maralixibat represents the first FDA-approved treatment for cholestatic pruritus in patients with Alagille syndrome. It was granted FDA approval on 29 September 2021.

  2. Drug

    Phenazopyridine

    go.drugbank.com/drugs/DB01438
    ApprovedInvestigational

    In the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world.

  3. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017.

  4. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]

  5. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

  6. Drug

    Duloxetine

    go.drugbank.com/drugs/DB00476
    ApprovedInvestigational

    [A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.

    Products: Nra-duloxetine
  7. Drug

    Latanoprost

    go.drugbank.com/drugs/DB00654
    ApprovedInvestigational

    It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment.

  8. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.

  9. Drug

    Indacaterol

    go.drugbank.com/drugs/DB05039
    ApprovedInvestigational

    It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.

  10. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis. … [A254157] On October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported that the benefit of treatment with daprodustat outweighs the risks for adult dialysis patients with